{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:13:30Z","timestamp":1777652010217,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":332,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.ctarc.2020.100254","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T09:43:21Z","timestamp":1606643001000},"page":"100254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Myositis \u2013 A common but underreported adverse effect of osimertinib: Case series and review of the literature"],"prefix":"10.1016","volume":"25","author":[{"given":"Pawel","family":"Parafianowicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohee","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce D.","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raheel X.","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejvir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2020.100254_bib0001","article-title":"What is lung cancer?","year":"2019","journal-title":"Am. Cancer Soc."},{"key":"10.1016\/j.ctarc.2020.100254_bib0002","article-title":"Lung cancer statistics","year":"2019","journal-title":"Center. Disease Control Prevent."},{"key":"10.1016\/j.ctarc.2020.100254_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non small cell lung cancer","author":"Schiller","year":"2002","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ctarc.2020.100254_bib0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2020.100254_bib0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2020.100254_bib0006","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100254_bib0007","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40264-017-0596-0","article-title":"Erlotinib plus bevacizumab Phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results","author":"Kato","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctarc.2020.100254_bib0008","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.ctarc.2020.100254_bib0009","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2020.100254_bib0010","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non\u2013small-cell lung cancer: American society of clinical oncology clinical practice guideline update","author":"Hanna","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100254_bib0011","author":"Soria","year":"2018","journal-title":"Osimertinib in Untreated EGFR-Mutated Adv.: New England J. Med."},{"key":"10.1016\/j.ctarc.2020.100254_bib0012","unstructured":"FDA. TAGRISSO\u2122 (osimertinib). www.fda.gov. November 2015. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208065s000lbl.pdf."},{"key":"10.1016\/j.ctarc.2020.100254_bib0013","article-title":"Osimertinib (TAGRISSO)","year":"2015","journal-title":"U. S. Food Drug Admin."},{"key":"10.1016\/j.ctarc.2020.100254_bib0014","unstructured":"FDA. www.fda.gov. April 18, 2018. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations."},{"key":"10.1016\/j.ctarc.2020.100254_bib0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non\u2013small-cell lung cancer: AURA study phase II extension component","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100254_bib0016","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2020.100254_bib0017","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/cas.13623","article-title":"Osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer: AURA3 trial","author":"Akamatsu","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctarc.2020.100254_bib0018","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer","author":"J\u00e4nne","year":"2015","journal-title":"The New England J. Medic."},{"key":"10.1016\/j.ctarc.2020.100254_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtho.2018.03.014","article-title":"Myositis in a patient with advanced lung cancer treated with osimertinib","author":"Fujioka","year":"2018","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2020.100254_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity","author":"Sathasivam","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ctarc.2020.100254_bib0021","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/psp4.12289","article-title":"Development, verification, and prediction of osimertinib drug\u2013drug interactions using PBPK modeling approach to inform drug label","author":"Reddy","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol"},{"key":"10.1016\/j.ctarc.2020.100254_bib0022","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1111\/bcp.13753","article-title":"Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin","author":"Harvey","year":"2018","journal-title":"Br. J. Clin. Pharmacol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:18:42Z","timestamp":1762841922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220300897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":22,"alternative-id":["S2468294220300897"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100254","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myositis \u2013 A common but underreported adverse effect of osimertinib: Case series and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100254"}}